These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 34249838)

  • 21. The biosimilar insulin landscape: current developments.
    Lavalle-González FJ; Khatami H
    Postgrad Med; 2014 Oct; 126(6):81-92. PubMed ID: 25414937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review.
    Saunders H; Pham B; Loong D; Mishra S; Ashoor HM; Antony J; Darvesh N; Bains SK; Jamieson M; Plett D; Trivedi S; Yu CH; Straus SE; Tricco AC; Isaranuwatchai W
    Value Health; 2022 Jul; 25(7):1235-1252. PubMed ID: 35341688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biosimilar Insulin and Costs: What Can We Expect?
    Heinemann L
    J Diabetes Sci Technol; 2015 Sep; 10(2):457-62. PubMed ID: 26350722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer.
    Hernandez I; Gellad WF
    J Manag Care Spec Pharm; 2020 Feb; 26(2):154-159. PubMed ID: 32011961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Policies for biosimilar uptake in Europe: An overview.
    Moorkens E; Vulto AG; Huys I; Dylst P; Godman B; Keuerleber S; Claus B; Dimitrova M; Petrova G; Sović-Brkičić L; Slabý J; Šebesta R; Laius O; Karr A; Beck M; Martikainen JE; Selke GW; Spillane S; McCullagh L; Trifirò G; Vella Bonanno P; Mack A; Fogele A; Viksna A; Władysiuk M; Mota-Filipe H; Meshkov D; Kalaba M; Mencej Bedrač S; Fürst J; Zara C; Skiöld P; Magnússon E; Simoens S
    PLoS One; 2017; 12(12):e0190147. PubMed ID: 29284064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis.
    Mansell K; Bhimji H; Eurich D; Mansell H
    BMC Health Serv Res; 2019 Nov; 19(1):827. PubMed ID: 31718624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
    Horvath K; Jeitler K; Berghold A; Ebrahim SH; Gratzer TW; Plank J; Kaiser T; Pieber TR; Siebenhofer A
    Cochrane Database Syst Rev; 2007 Apr; (2):CD005613. PubMed ID: 17443605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The price paradox of biosimilar-like long-acting insulin.
    Mouslim MC; Rashidi ES; Levy JF; Socal MP; Trujillo AJ
    Am J Manag Care; 2022 Nov; 28(11):e405-e410. PubMed ID: 36374658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Key drivers for market penetration of biosimilars in Europe.
    Rémuzat C; Dorey J; Cristeau O; Ionescu D; Radière G; Toumi M
    J Mark Access Health Policy; 2017; 5(1):1272308. PubMed ID: 28265349
    [No Abstract]   [Full Text] [Related]  

  • 30. Assessing the Structural and Functional Similarity of Insulin Glargine Biosimilars.
    Vishwakarma G; Nupur N; Rathore AS
    J Diabetes Sci Technol; 2023 Mar; 17(2):417-427. PubMed ID: 34852652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
    Dutta B; Huys I; Vulto AG; Simoens S
    BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The past, present, and future of basal insulins.
    Pettus J; Santos Cavaiola T; Tamborlane WV; Edelman S
    Diabetes Metab Res Rev; 2016 Sep; 32(6):478-96. PubMed ID: 26509843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries.
    Klein K; Gencoglu M; Heisterberg J; Acha V; Stolk P
    BioDrugs; 2023 Mar; 37(2):235-245. PubMed ID: 36472773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biosimilar insulins: a European perspective.
    DeVries JH; Gough SC; Kiljanski J; Heinemann L
    Diabetes Obes Metab; 2015 May; 17(5):445-51. PubMed ID: 25376600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea.
    Lee HJ; Han E; Kim H
    Appl Health Econ Health Policy; 2020 Aug; 18(4):557-566. PubMed ID: 31930450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The advent of biosimilars for the treatment of diabetes: current status and future directions.
    Polimeni G; Trifirò G; Ingrasciotta Y; Caputi AP
    Acta Diabetol; 2015 Jun; 52(3):423-31. PubMed ID: 25990669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding Biosimilar Insulins - Development, Manufacturing, and Clinical Trials.
    Heinemann L; Davies M; Home P; Forst T; Vilsbøll T; Schnell O
    J Diabetes Sci Technol; 2023 Nov; 17(6):1649-1661. PubMed ID: 35818669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Innovative insulins--where do analogues fit?
    Phillips LK; Phillips PJ
    Aust Fam Physician; 2006 Dec; 35(12):969-73. PubMed ID: 17149471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin biosimilars: the impact on rapid-acting analogue-based therapy.
    Franzè S; Cilurzo F; Minghetti P
    BioDrugs; 2015 Apr; 29(2):113-21. PubMed ID: 25773234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. European Stakeholder Learnings Regarding Biosimilars: Part I-Improving Biosimilar Understanding and Adoption.
    Barbier L; Simoens S; Vulto AG; Huys I
    BioDrugs; 2020 Dec; 34(6):783-796. PubMed ID: 33141421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.